Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer’s disease and Parkinson’s disease
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Nicotinic systems play an important role in the neural basis of working memory and attention. Recent progress in understanding of the structure, function, and distribution of central nervous system (CNS) nicotinic receptors and their pharmacology has opened up new possibilities for novel CNS therapeutics with nicotinic agents. In this paper, we review the theoretical justification and the experimental evidence supporting these developments. We focus on the applications of nicotinic agonists in CNS disorders that are degenerative in nature, namely Parkinson's disease and Alzheimer's disease. We suggest that there is considerable potential for therapeutic applications in the near future. Clinically, two major issues remain: (a) the selectivity of effects, that is, developing compounds which are selective in producing improvement in cognition, motor function, attention, or pain without significant side-effects; and (b) the realistic likelihood of long-term improvements in everyday functioning in people who have degenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors
McGehee, D. S., Heath, M. J. S., Gelber, S., Devay, P., & Role, L. W. (1995) · Science · doi:10.1126/science.7569895 · Cited by 1,070
Potter, A., Corwin, J., Lang, J., Piasecki, M., Lenox, R., & Newhouse, P. A. (1999) · Psychopharmacology · doi:10.1007/s002130050897 · Cited by 163
Self-citationWang, H.-X., Fratiglioni, L., Frisoni, G. B., Viitanen, M., & Winblad, B. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009864 · Cited by 110
Cited by
Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system
Taly, A., Corringer, P.-J., Guedin, D., Lestage, P., & Changeux, J.-P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2927 · Cited by 703
Nicotinic acetylcholine receptors: from structure to brain function
Hogg, R. C., Raggenbass, M., & Bertrand, D. (2003) · Reviews of Physiology, Biochemistry and Pharmacology · doi:10.1007/s10254-003-0005-1 · Cited by 528
Alternate stoichiometries of α4β2 nicotinic acetylcholine receptors
Nelson, M. E., Kuryatov, A., Choi, C. H., Zhou, Y., & Lindstrom, J. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.2.332 · Cited by 422
“They also are thought to be involved in Alzheimer’s and Parkinson’s diseases (Rusted et al., 2000).”
BackgroundAdvances in the treatment of Parkinson's disease
Singh, N., Pillay, V., & Choonara, Y. E. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.009 · Cited by 394
Nicotinic receptor subtypes and cognitive function
Levin, E. D. (2002) · Journal of Neurobiology · doi:10.1002/neu.10151 · Cited by 354
Self-citation
Metadata
- Authors
- Rusted, J. M., Newhouse, P. A., & Levin, E. D.
- Venue
- Behavioural Brain Research
- Publisher
- Elsevier BV
- Published
- 2000-08
- Volume
- 113
- Issue
- 1-2
- Pages
- 121-129
- ISSN
- 0166-4328 (ISSN-L)
- OpenAlex
- W2029591728
- Cited by
- 92
- References
- 3
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer’s disease and Parkinson’s disease. https://app.cochat.ai/papers/10.1016/s0166-4328(00)00207-2
- The paper
- Rusted, J. M., Newhouse, P. A., & Levin, E. D. (2000). Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer’s disease and Parkinson’s disease. Behavioural Brain Research. https://doi.org/10.1016/s0166-4328(00)00207-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.